P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents

Cardiology

Volumn 112, Issue 4, 2009, Pages 263-269

  Tiroch, K ^a,c   Koch, W ^a   Mehilli, J ^a   Bottiger C ^a   Schomig A ^b   Kastrati, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Drug eluting stent; P27; P53; Polymorphism; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PROTEIN P27; PROTEIN P53;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ELUTING STENT; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTENOSIS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COHORT STUDIES; CORONARY ARTERY DISEASE; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG-ELUTING STENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 50349089373     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151695     Document Type: Article

References (34)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting Taxus stent: the Taxus-IV trial. Circulation 2004;109:1942-1947.
4. Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, et al: Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005;293:165-171.
5. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, et al: Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670.
6. Popma JJ, Leon MB, Moses JW, Holmes DR Jr, Cox N, Fitzpatrick M, et al: Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation 2004;110:3773-3780.
7. Suh JW, Park JS, Cho HJ, Kim MS, Kang HJ, Cho YS, et al: Sirolimus-eluting stent showed better one-year outcomes than paclitaxel-eluting stent in a real life setting of coronary intervention in Koreans. Int J Cardiol 2007;117:31-36.
8. Lee CW, Park KH, Kim YH, Hong MK, Kim JJ, Park SW, et al: Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions. Am J Cardiol 2006;98:918-922.
9. Schomig A, Kastrati A, Elezi S, Schuhlen H, Dirschinger J, Dannegger F, et al: Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. Circulation 1997;96:3880-3887.
10. Kastrati A, Schomig A, Elezi S, Schuhlen H, Wilhelm M, Dirschinger J: Interlesion dependence of the risk for restenosis in patients with coronary stent placement in multiple lesions. Circulation 1998;97:2396-2401.
11. Dumont FJ, Su Q: Mechanism of action of the immunosuppressant rapamycin. Life Sci 1996;58:373-395.
12. Woltman AM, van der Kooij SW, Coffer PJ, Offringa R, Daha MR, van Kooten C: Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased P27KIP1 expression. Blood 2003;101:1439-1445.
13. Pasquier E, Carre M, Pourroy B, Camoin L, Rebai O, Briand C, et al: Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004;3:1301-1310.
14. Pilotti S, Oggionni M, Bohm S, Pierotti MA, Zunino F: ICON3 and chemotherapy for ovarian cancer. Lancet 2002;360:2087-2088; author reply 2088.
15. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V: Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 2003;3:291-306.
16. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene P27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177-180.
17. Baens M, Wlodarska I, Corveleyn A, Hoornaert I, Hagemeijer A, Marynen P: A physical, transcript, and deletion map of chromosome region 12p12.3 flanked by ETV6 and CDKN1B: hypermethylation of the LRP6 CpG island in two leukemia patients with hemizygous del(12p). Genomics 1999;56:40-50.
18. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al: Mice lacking P27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-720.
19. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of P27(Kip1). Cell 1996;85:721-732.
20. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in P27(Kip1)-deficient mice. Cell 1996;85:733-744.
21. Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, et al: A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004;64:1997-1999.
22. Wu CC, Shete S, Amos CI, Strong LC: Joint effects of germ-line P53 mutation and sex on cancer risk in Li-Fraumeni syndrome. Cancer Res 2006;66:8287-8292.
23. Yamada T, Maruyama M, Fujita T, Miyabayashi K, Shinoda C, Kawagishi Y, et al: Ionizing radiation suppresses FAP-1 mRNA level in A549 cells via P53 activation. FEBS Lett 2006;580:4387-4391.
24. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M: The codon 72 polymorphic variants of P53 have markedly different apoptotic potential. Nat Genet 2003;33:357-365.
25. Schomig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
26. Livak KJ: Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999;14:143-149.
27. Kastrati A, Schomig A, Seyfarth M, Koch W, Elezi S, Bottiger C, et al: PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation 1999;99:1005-1010.
28. Alkhalaf M, Al-Bustan S, Hamoda H, Abdella N: Polymorphism of P53 gene codon 72 in Kuwaiti with coronary artery disease and diabetes. Int J Cardiol 2007;115:1-6.
29. Kastrati A, Dibra A, Eberle S, Mehilli J, Suarez de Lezo J, Goy JJ, et al: Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 2005;294:819-825.
30. Sidhu S, Shafiq N, Malhotra S, Pandhi P, Grover A: A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease. Br J Clin Pharmacol 2006;61:720-726.
31. Biondi-Zoccai GG, Agostoni P, Abbate A, Testa L, Burzotta F, Lotrionte M, et al: Adjusted indirect comparison of intracoronary drug-eluting stents: evidence from a meta-analysis of randomized bare-metal-stent-controlled trials. Int J Cardiol 2005;100:119-123.
32. Amant C, Bauters C, Bodart JC, Lablanche JM, Grollier G, Danchin N, et al: D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 1997;96:56-60.
33. Tiroch K, Koch W, von Beckerath N, Kastrati A, Schomig A: Heme oxygenase-1 gene promoter polymorphism and restenosis following coronary stenting. Eur Heart J 2007;28:968-973.
34. Koch W, Tiroch K, von Beckerath N, Schomig A, Kastrati A: Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 2003;24:161-171.